Wegovy Before and After 1 Month: What the Pictures Really Show

Semaglutide (Wegovy) starts at 0.25 mg for the first four weeks — a tolerability dose designed to settle your system, not produce peak weight loss.
In the STEP 1 clinical trial, average weight loss over 68 weeks was around 15%; the first month represents only a fraction of that trajectory.
Visible changes at one month vary widely: some people notice clear differences, others see little outward shift while internal metabolic changes are already under way.
One-month photos circulating online frequently mix different starting doses, different time points and body types, direct comparisons are rarely like-for-like.

Photos taken one month into Wegovy often show modest but real change — a slightly less bloated midsection, clothes sitting differently, a face that looks a little leaner. At the 2.5 mg starting dose, most people are still adjusting to the medicine, so dramatic one-month before-and-after pictures should be read with healthy scepticism. Wegovy is a prescription-only medicine licensed in the UK for weight management in adults; a prescriber assesses whether it is suitable for you before any treatment begins. The overview of Wegovy on this site covers the full picture, but if you want to understand specifically what is and is not realistic to see in early Wegovy before and after pictures at the one-month mark, the following is an honest, evidence-based account.

Starting from £29.99/mo

Free 2-minute consultation · Reviewed same day

Start journey
The nume Promise

Order by 12pm.

At your door the next working day.
Free, tracked, plain packaging.

Guaranteed on approved orders

Where are you starting from?

BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.

Check your BMI.

Ten seconds. Private — nothing is stored or shared.

80 kg
170 cm

Your result updates live in the card alongside.

Your result

Your BMI is

which is in the healthy weight range

Start journey

BMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.

Treatment options

Weight loss treatments

The problem

Most weight loss services treat you like a transaction, a checkout, a courier, and you're on your own.

Algorithm approvalsNo real clinicianGeneric dosingHidden feesSlow deliverySilence after checkout

The nume way

We built the opposite: one clinician who knows you, guaranteed care at every step.

24 hrs

clinician review. Free next working day delivery.

How it works

From consultation to your door, properly.

Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.

Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.

Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.

A realistic, step-by-step account of what happens in the first month on Wegovy

Step 1: Week one, the medicine arrives, your appetite starts to shift

The first pen delivers 0.25 mg once weekly. It is worth knowing that this dose was chosen specifically to reduce side effects, not to maximise fat loss. Within days, many people notice their appetite feels different: meals feel filling sooner, the mental pull towards food between mealtimes is quieter. These changes are real and clinically meaningful, but they do not yet translate into dramatic physical change. Most people lose between one and three kilograms in the first four weeks, though some lose more and some less, individual responses vary considerably depending on starting weight, diet and activity. A common misconception is that a slow first month means the medicine is not working; the early weeks are more about establishing tolerance than delivering measurable results, and the trajectory typically accelerates once the dose increases.

The NHS patient guidance on semaglutide confirms that the 0.25 mg starting dose is an introductory one, with the prescriber titrating upwards over subsequent months. Reading that guidance alongside any before and after pictures gives a much more grounded sense of what the photos are actually capturing.

Step 2: Weeks two to four, what the camera can and cannot capture

By the end of the first month, some people do have photos that show a visible difference. Faces tend to show change earlier than torsos. Waistlines may look slightly less full, particularly if early weight loss has reduced water retention alongside fat. But a photograph is a limited document. Lighting, posture, clothing, time of day and how recently someone ate all affect what a one-month image looks like. The Wegovy before and after pictures that travel furthest online are the striking ones, which selects for outliers. People who lose four or five kilograms in the first month exist, but they are not the median experience. For a fuller sense of how results develop over time, three-month before and after pictures tend to be more representative of meaningful change.

It is also worth looking at results broken down by sex and body type. Patterns in female before and after Wegovy pictures can differ from aggregate trial data, partly because women and men tend to carry and lose weight differently.

Step 3: Understanding the clinical evidence behind one-month photos

The STEP 1 trial, published in the New England Journal of Medicine, followed 1,961 adults over 68 weeks at the full 2.4 mg maintenance dose and recorded an average weight reduction of around 15%. That figure is spread across more than a year, not one month. What one-month data from that trial and related analyses suggests is that roughly a third of the eventual total loss typically occurs in the first twelve weeks, meaning the bulk of visible change comes later. The broader collection of Wegovy weight loss before and after pictures on this site contextualises that timeline clearly.

For people curious about how long the medicine takes to work in a more clinical sense, the page on how long Wegovy takes to work addresses the dose-by-dose trajectory in detail. And if you are weighing Wegovy against other injectable medicines, the semaglutide and B12 combination page explains a different clinical approach some providers use. The cost of a longer course of treatment is something many people ask about early on; the Wegovy price comparison page sets out what UK private pricing typically looks like across providers.

Step 4: What genuinely influences how much you see in month one

Starting weight matters. Someone beginning treatment at a higher BMI tends to see more absolute change early on, even if the percentage loss is similar to a lighter person. Adherence to the recommended dietary adjustments (smaller portions, reduced ultra-processed food) amplifies the medicine's appetite-lowering effect. Sleep, stress and how well-hydrated someone is also affect water retention, which is a real component of early weight change that does not always show in photos. Side effects in week one or two (nausea is the most commonly reported) sometimes reduce food intake so sharply that early results look striking, but this does not always persist as tolerance develops. A calmer, sustained reduction in appetite is generally a more reliable driver of long-term change. For anyone thinking about starting treatment, the weight loss treatment overview explains the options available and what a clinical assessment involves. Our clinical team reviews every consultation personally. Speak to our prescribers to understand what is realistic for your situation before month one even begins.

Looking to start your weight loss journey?
Take a quick eligibility quiz to explore your options and see how we can support you.
Start free consultation

The people

Meet the team.

Mahommed Zunaid Ayub Patel

Superintendent Pharmacist (GPhC No. 2217101)

Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.

Mostafa Damghani

Clinical Lead (GPhC No. 2231744)

Sets our clinical standards and checks everything we publish against current MHRA guidance.

Shelan Salih

Independent Prescriber (GPhC No. 2084501)

Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.

Rehenaaz Uddin

Independent Prescriber (GPhC No. 2083426)

Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.

Frequently asked questions